Researchers have learned how bacteria naturally make many versions of powerful cancer medicines. This new knowledge could help scientists create better drugs faster.
For a long time, scientists wanted to use bacterial enzymes to build new drug variants. They called this idea "combinatorial biosynthesis." The main problem was that nobody fully understood how the enzymes worked together.
A recent study in Nature Communications shows how bacterial enzymes talk to each other to make a family of related anti‑cancer compounds. One of these compounds is Romidepsin (brand name Istodax), an FDA‑approved treatment for certain blood cancers. By copying the natural "mix‑and‑match" system in the lab, researchers now have a new way to design future cancer medicines.
Tiny Connectors Guide Drug Assembly
The team found tiny protein regions called docking domains. These act like connectors between the core drug‑making machine and the enzymes that add different parts. The docking domains have a shared contact point, so they can bind to many enzyme partners.
This flexible design lets bacteria produce a variety of similar drug molecules while keeping each one precise enough to work well.
How the System Evolved
The scientists think the newly discovered compound grew out of an older drug‑making pathway. Over time, gene duplication and reshuffling created the new version.
Professor Greg Challis, a sustainable chemistry expert, said the work gives a "blueprint" to copy nature’s tricks but do it faster and better. By understanding nature’s logic, we can now design synthetic pathways that make new cancer‑drug candidates with stronger effects, better selectivity, and fewer side effects. The goal is to build a larger library of candidates for cancers that still need better treatments.
Impact on Cancer Drug Development
The study focuses on a group of medicines called HDAC inhibitors. These drugs block enzymes that control which genes are turned on or off in cells. Romidepsin is an FDA‑approved HDAC inhibitor used for T‑cell lymphomas.
A related compound, FR‑901375, has been known for years, but scientists never knew how bacteria make it. This research finally fills that gap.
Like other HDAC inhibitors, FR‑901375 belongs to a class of complex ring‑shaped molecules called depsipeptides. Bacteria build these molecules using huge protein machines called PKS‑NRPS hybrids, which combine the actions of polyketide synthase (PKS) and non‑ribosomal peptide synthetase (NRPS). The docking domains act as molecular connectors, letting one part of the assembly line hand its product to the next, enabling natural combinatorial biosynthesis.
How the Scientists Solved the Puzzle
The research team used many tools, including:
- Database searches that found the FR‑901375 gene cluster in Pseudomonas chlororaphis subsp. piscium, confirmed by mass‑spectrometry of bacterial extracts.
- Lab experiments that mixed purified protein pieces together, showing they interact correctly.
- AlphaFold computer models to predict how the proteins fit, followed by carbene footprinting to map real contact spots.
- Targeted mutations that proved the predicted binding spots are essential.
- Gene‑deletion tests in bacteria that showed removing docking domains stops the system from working.
- Comparisons of gene clusters from many HDAC‑producing bacteria, revealing shared features across nature’s drug factories.
These findings give scientists a clear map of how bacteria create diverse cancer drugs. With this map, we can now engineer new pathways to make even better medicines for patients who need them.